3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Modified FOLFOX6: new trials by email Literature Review of Modified FOLFOX6 trials Research Report on Modified FOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Gevokizumab, Bevacizumab, Modified FOLFOX6 - Colorectal Cancer, Gastroesophageal Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 167 | 2019-05-22 | 2026-04-01 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer Bemarituzumab, Modified FOLFOX6 - Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 12 | 2017-11-30 | 2024-02-28 |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer Placebo, AMG 655, Modified FOLFOX6 - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Amgen | 202 | 2007-10-01 | 2014-04-25 |
Colorectal Neoplasms (2) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Amgen (1) · Five Prime Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1)
United States (3) · Australia (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
2018 (1)